Neurol. praxi. 2026;27(3):194-199 | DOI: 10.36290/neu.2026.032

Integrated approach to the treatment of spastic paresis using botulinum toxin and physiotherapy

Mgr. Ota Gál, Ph.D., prof. MUDr. Robert Jech, Ph.D., Mgr. Václav Matys, MUDr. Martina Hoskovcová, Ph.D.
Neurologická klinika a Centrum klinických neurověd, 1. LF UK, VFN v Praze

Spastic paresis represents a complex clinical syndrome and it's management requires an integrated approach combining pharmacological interventions with targeted physiotherapy. This article summarizes key aspects of the pathophysiology, assessment, and treatment of spastic paresis, with particular emphasis on the role of botulinum toxin and contemporary physiotherapeutic approaches. The aim is to provide practical guidance for optimizing treatment plans in patients with spastic paresis.

Keywords: spastic paresis, muscle overactivity, botulinum toxin, physiotherapy.

Received: January 22, 2026; Revised: March 12, 2026; Accepted: June 17, 2026; Prepublished online: June 17, 2026; Published: July 20, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gál O, Jech R, Matys V, Hoskovcová M. Integrated approach to the treatment of spastic paresis using botulinum toxin and physiotherapy. Neurol. praxi. 2026;27(3):194-199. doi: 10.36290/neu.2026.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 20.7.2027

    References

    1. Ada L, O'Dwyer N, O'Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disabil Rehabil. 2006 Jul 15-30;28(13-14):891-7. Go to original source...
    2. Alter KE, Karp BI. Ultrasound Guidance for Botulinum Neurotoxin Chemodenervation Procedures. Toxins (Basel). 2017 Dec 28;10(1):18. Go to original source...
    3. Ashford S, Turner-Stokes L, Allison R, et al. Spasticity in adults: management using botulinum toxin. National guidelines. Second Edition 2018.
    4. Ashford S, Williams H, Nair A, et al. Categorisation of goals set using Goal Attainment Scaling for treatment of leg spasticity: a multicentre analysis. Disabil Rehabil. 2019 Aug;41(16):1925-1930. Go to original source...
    5. Baude M, Nielsen JB, Gracies JM. The neurophysiology of deforming spastic paresis: a revised taxonomy. Ann Phys Rehabil Med. 2019 Nov;62(6):426-430. Go to original source...
    6. Blumetti FC, Belloti JC, Tamaoki MJ, et al. Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy. Cochrane Database Syst Rev. 2019 Oct 8;10(10):CD001408. Go to original source...
    7. Bohart Z, Dashtipour K, Kim H, et al. Real-world differences in dosing and clinical utilization of Onabotulinumtoxin A and Abobotulinumtoxin A in the treatment of upper limb spasticity. Toxicon. 2024 Apr;241:107678. Go to original source...
    8. Burridge JH, Taylor PN, Hagan SA, et al. The effects of common peroneal stimulation on the effort and speed of walking: a randomized controlled trial with chronic hemiplegic patients. Clin Rehabil. 1997;11(3):201-10. Go to original source...
    9. Butland RJ, Pang J, Gross ER, et al. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982;284(6329):1607-8. Go to original source...
    10. Chang E, Ghosh N, Yanni D, et al. A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Crit Rev Phys Rehabil Med. 2013;25(1-2):11-22. Go to original source...
    11. Cramer SC, Sur M, Dobkin BH, et al. Harnessing neuroplasticity for clinical applications. Brain. 2011 Jun;134(Pt 6):1591-609. Go to original source...
    12. Deltombe T, Wautier D, De Cloedt P, et al. Assessment and treatment of spastic equinovarus foot after stroke: Guidance from the Mont-Godinne interdisciplinary group. J Rehabil Med. 2017 Jun 28;49(6):461-468. Go to original source...
    13. Dressler D, Altavista MC, Altenmueller E, et al. Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. J Neural Transm (Vienna). 2021 Mar;128(3):321-335. Go to original source...
    14. Dressler D, Bhidayasiri R, Bohlega S, et al. Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. J Neurol. 2018 Apr;265(4):856-862. Go to original source...
    15. Gál O, Baude M, Deltombe T, et al. Clinical Outcome Assessments for Spasticity: Review, Critique, and Recommendations. Mov Disord. 2025b Jan;40(1):22-43. Go to original source...
    16. Gál O, Hoskovcová M, Srp M, et. al. Poruchy chůze u spastických syndromů. In: Hoskovcová M, Gál O, Růžička E, eds. Poruchy chůze a stability. Projevy, příčiny, diferenciální diagnostika, léčba. Grada 2025a.
    17. Gracies JM, Alter KE, Biering-Sørensen B, et al. SpasticParesis: A Treatable Movement Disorder. Mov Disord. 2025 Jan;40(1):44-50. Go to original source...
    18. Gracies JM, Bayle N, Vinti M, et al. Five-step clinical assessment in spastic paresis. Eur J Phys Rehabil Med. 2010 Sep;46(3):411-21.
    19. Gracies JM, Francisco GE, Jech R, et al. Guided Self-rehabilitation Contracts Combined With Abobotulinumtoxin A in Adult sWith Spastic Paresis. J Neurol Phys Ther. 2021;45:203-213. Go to original source...
    20. Gracies JM, Marosszeky JE, Renton R, et al. Short-term effects of dynamic lycra splints on upper limb in hemiplegic patients. Arch Phys Med Rehabil. 2000 Dec;81(12):1547-55. Go to original source...
    21. Gracies JM. Coefficients of impairment in deformit spastic paresis. Ann Phys Rehabil Med. 2015 Jun;58(3):173-8. Go to original source...
    22. Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve. 2005a May;31(5):535-51. Go to original source...
    23. Gracies JM. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve. 2005b May;31(5):552-71. Go to original source...
    24. Gracies JM. Physiological effects of botulinum toxin in spasticity. MovDisord. 2004 Mar;19 Suppl8:S120-8. Go to original source...
    25. Gross R, Verduzco-Gutierrez M, Draulans N, et al. Module 3: Surgical management of spasticity. J Int Soc Phys Rehabil Med. 2022;5:S38-49. Go to original source...
    26. Hoskovcova M, Baude M, Biering-Sørensen B, Gal O, Galea MP, Gracies JM, Rodriguez-Blazquez C, Wein T, Tosin MHS, Sánchez-Ferro Á, Mestre TA, Skorvanek M, Jech R; members of the MDS Clinical Outcome Assessments Scientific Evaluation Committee and MDS Spasticity Study Group. Clinical Outcome Assessments for Functional Performance in Spastic Paresis: Systematic Review, Critique, and Recommendations. Mov Disord. 2026 Mar 30. doi: 10.1002/mds.70288. Epub ahead of print. PMID: 41909919. Go to original source... Go to PubMed...
    27. Jech R, Gál O, Angerová Y, et al. NAVIGAČNÍ ATLAS svalů horní a dolní končetiny pro aplikace botulotoxinu Neuropa Centrum, 2024.
    28. Kimberley TJ, Samargia S, Moore LG, et al. Comparison of amounts and types of practice during rehabilitation for traumatic brain injury and stroke. J Rehabil Res Dev. 2010;47(9):851-62. Go to original source...
    29. Kwak S, Kang WH, Rhee CH, et al. Comparative Pharmacodynamics Study of 3 Different Botulinum Toxin Type A Preparations in Mice. Dermatol Surg. 2020 Dec;46(12):e132-e138. Go to original source...
    30. Laclergue Z, Ghédira M, Gault-Colas C, et al. Reliability of the Modified Frenchay Scale for the Assessment of Upper Limb Function in Adults With Hemiparesis. Arch Phys Med Rehabil. 2023 Oct;104(10):1596-1605. Go to original source...
    31. Lang CE, Macdonald JR, Reisman DS, et al. Observation of amounts of movement practice provided during stroke rehabilitation. Arch Phys Med Rehabil. 2009 Oct;90(10):1692-8. Go to original source...
    32. Lecharte T, Gross R, Nordez A, et al. Effect of chronic stretching interventions on the mechanical properties of muscles in patients with stroke: A systematic review. Ann Phys Rehabil Med. 2020 May;63(3):222-229. Go to original source...
    33. Lindsay C, Kouzouna A, Simcox C, et al. Pharmacological interventions other than botulinum toxin for spasticity after stroke. Cochrane Database Syst Rev. 2016 Oct 6;10:CD010362. Go to original source...
    34. Lízrová-Preiningerová J. Symptomatická terapie roztroušené sklerózy: Léčba spasticity a poruch chůze. In: E. Havrdová a kol. (ed.). Roztroušená skleróza. Mladá Fronta, Praha 2013.
    35. Lorentzen J, Pradines M, Gracies JM, et al. On Denny-Brown's 'spastic dystonia' - What is it and what causes it? Clin Neurophysiol. 2018 Jan;129(1):89-94. Go to original source...
    36. Oujamaa L, Relave I, Froger J, et al. Rehabilitation of arm function after stroke. Literature review. Ann Phys Rehabil Med. 2009 Apr;52(3):269-93. Go to original source...
    37. Pradines M, Ghédira M, Bignami B, et al. Do Muscle Changes Contribute to the Neurological Disorder in Spastic Paresis? Front Neurol. 2022 Mar;14(13):817229. Go to original source...
    38. Santamato A, Micello MF, Ranieri M, et al. Employment of higherdoses of botulinum toxin type A to reduce spasticity afterstroke. J Neurol Sci. 2015 Mar 15;350(1-2):1-6. Go to original source...
    39. Scaglione F. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel). 2016 Mar 4;8(3):65. Go to original source...
    40. Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movementdisorders (an evidence-basedreview) [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 6;70(19):1699-706. Go to original source...
    41. Štětkářová I. Perorální léčba spasticity. In: Štětkářová I, Ehler E, Jech R (eds.). Spasticita a jejíléčba. Maxdorf, Praha 2012.
    42. Wade DT, Wood VA, Heller A, et al. Walking after stroke. Measurement and recovery over the first 3 months. Scand J Rehabil Med. 1987;19(1):25-30. Go to original source...
    43. Winstein C, Kim B, Kim S, et al. Dosage Matters. Stroke. 2019 Jul;50(7):1831-1837. Go to original source...
    44. Winston P, Branco Mills P, Reebye R, et al. Cryoneurotomy as a Percutaneous Mini-invasive Therapy for the Treatment of the Spastic Limb: Case Presentation, Review of the Literature, and Proposed Approach for Use. Arch Rehabil Res Clin Transl. 2019 Dec;1(3-4):100030. Go to original source...
    45. Wissel J, Camões-Barbosa A, Carda S, et al. A practical guide to botulinum neurotoxin treatment of shoulder spasticity 2: Injection techniques, outcome measurement scales, and case studies. Front Neurol. 2022 Dec 7;13:1022549. Go to original source...
    46. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009 Jan;41(1):13-25. Go to original source...
    47. Zorowitz RD, Jacinto J, Ashford S, et al. Muscle selection and dosing in patiens undergoing treatment with abobotulinum toxin A for lower limb spasticity in real-world practice. J Rehabil Med. 2025 Feb 7;57:jrm42605. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.